Alaunos Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Alaunos Therapeutics, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Alaunos Therapeutics has little or no product revenue yet; it used $3m of cash in the twelve months to June 2026. The diluted share count is up 37.3% on a year earlier, which dilutes existing holders. It passes 1 of our 2 financial-health checks.
Our model value for Alaunos Therapeutics is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Alaunos Therapeutics, Inc.'s trailing-twelve-month revenue fell 50.0% year on year, with a free-cash-flow margin of -90900.0%.
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 280% in the quarter to 2023-12-31.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
| At fiscal year end | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Now |
|---|---|---|---|---|---|---|---|---|---|---|
| Share price | $802.50 | $621.00 | $280.50 | $378.00 | $163.50 | $97.50 | $10.50 | $1.91 | $3.23 | $1.75 |
| Market value | $698m | $567m | $269m | $528m | $234m | $141m | $17m | $3m | $6m | $4m |
| + Net debt (− = net cash) | −$81m | −$71m | −$62m | −$115m | −$52m | −$22m | −$6m | −$1m | −$1m | −$124000 |
| Enterprise value | $617m | $496m | $207m | $413m | $182m | $119m | $11m | $2m | $5m | $4m |
| Multiples | ||||||||||
| Price / sales | 101.7x | 35.7x | n/m | — | n/m | 48.3x | n/m | n/m | n/m | n/m |
| Price / earnings | — | — | — | — | — | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
Weak moat
How hard Alaunos Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Net income has been a median -77.6% of total assets over 10 years.
Operating margin has been a median -11229.6%; its worst year was -325350.0%.
Free cash flow was positive in 0 of 7 years, at a median -9114.2% of revenue.
The diluted share count rose 117.2% over five years; stock-based pay has been a median 542.5% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).
No analyst estimates are published for Alaunos Therapeutics, Inc.: too few analysts cover it.
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Dec 2023 | −$4.50 | −$17.09 | −279.9% |
| Sept 2023 | −$5.25 | −$4.41 | +16.0% |
| Jun 2023 | −$6.75 | −$6.00 | +11.1% |
| Mar 2023 | −$6.60 | −$6.00 | +9.1% |
Adjusted EPS as companies report it, against the average analyst estimate.
Last 12 months −35.7%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $6000 | $3000 | −50.0% |
| P/S multiple | n/m | n/m | +76.6% |
| Share count | 2m | 2m | −27.1% |
Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.
Last 3 years −85.4%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $3m | $3000 | −99.9% |
| P/S multiple | 6.2x | n/m | +20766.6% |
| Share count | 2m | 2m | −31.8% |
Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| TCRT | −57% | −40% | −89% | −82% | +69% | −46% |
| Industry peers (median) | −35% | −57% | −17% | −28% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| TCRT | 25% | 25% | 25% | 25% | 50% | 27% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| TCRT | −81% | −86% | −95% | −94% | −66% | −80% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since October 29, 2015: 100% from November 10, 2015 to October 6, 2026. Getting back needed a 295238% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| October 10, 2024 | −4.1% | +0.4% | +0.5% | −10.0% |
| November 14, 2023 | 0.0% | +2.2% | −12.5% | −37.5% |
| August 14, 2023 | −65.0% | −0.6% | −65.0% | −70.0% |
| May 10, 2023 | −3.3% | +0.3% | +5.0% | −23.3% |
| March 7, 2023 | +3.4% | −1.4% | −12.1% | +5.2% |
| November 14, 2022 | −5.6% | 0.0% | −10.2% | −38.0% |
| August 15, 2022 | +12.1% | +0.6% | −1.2% | +105.5% |
| May 16, 2022 | −11.9% | +1.6% | −11.9% | +44.1% |
| March 30, 2022 | −5.8% | −2.1% | −14.5% | −23.2% |
| August 9, 2021 | −15.4% | 0.0% | −25.6% | −15.0% |
| May 6, 2021 | +5.6% | +1.5% | 0.0% | −1.0% |
| February 25, 2021 | +8.8% | −2.9% | −12.0% | −25.5% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $15K |
| FY23 Q4 | $5K |
| FY24 Q1 | $6K |
| FY24 Q2 | $6K |
| FY24 Q3 | $6K |
| FY24 Q4 | $9K |
| FY25 Q1 | $10K |
| FY25 Q2 | $6K |
| FY25 Q3 | $6K |
| FY25 Q4 | $5K |
| FY26 Q1 | $3K |
| FY26 Q2 | $3K |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY13 Q4 | 0.0% |
| FY18 Q4 | -97.7% |
| FY24 Q1 | -99.8% |
| FY24 Q2 | -99.8% |
| FY24 Q3 | -60.0% |
| FY24 Q4 | 80.0% |
| FY25 Q1 | 66.7% |
| FY25 Q2 | 0.0% |
| FY25 Q3 | 0.0% |
| FY25 Q4 | -44.4% |
| FY26 Q1 | -70.0% |
| FY26 Q2 | -50.0% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | -232260.0% |
| FY23 Q4 | -685340.0% |
| FY24 Q1 | -438950.0% |
| FY24 Q2 | -325350.0% |
| FY24 Q3 | -200116.7% |
| FY24 Q4 | -53477.8% |
| FY25 Q1 | -41630.0% |
| FY25 Q2 | -67266.7% |
| FY25 Q3 | -67883.3% |
| FY25 Q4 | -84500.0% |
| FY26 Q1 | -138166.7% |
| FY26 Q2 | -135266.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q3 | -201333.3% |
| FY23 Q4 | -606780.0% |
| FY24 Q1 | -380233.3% |
| FY24 Q2 | -289300.0% |
| FY24 Q3 | -196066.7% |
| FY24 Q4 | -55233.3% |
| FY25 Q1 | -38260.0% |
| FY25 Q2 | -47433.3% |
| FY25 Q3 | -48483.3% |
| FY25 Q4 | -57380.0% |
| FY26 Q1 | -104266.7% |
| FY26 Q2 | -90900.0% |
| Fiscal year | 2011 Dec 2011 | 2012 Dec 2012 | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||||
| Revenue | 1 | 1 | 7 | 16 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| EBITDA | −71 | −102 | −165 | −53 | −53 | −79 | −75 | −32 | −32 | −5 | −4 | −4 |
| Operating income | −71 | −102 | −165 | −53 | −54 | −80 | −78 | −35 | −34 | −5 | −4 | −4 |
| Net income | −64 | −96 | −165 | −54 | −53 | −80 | −79 | −38 | −5 | −5 | −4 | −4 |
| Diluted EPS | −$145.50 | −$1.22 | −$1.32 | −$0.53 | $0.96 | −$57.00 | −$0.37 | −$26.10 | −$21.97 | −$2.92 | −$2.20 | −$1.80 |
| Growth (year on year) | ||||||||||||
| Revenue | — | +19.9% | +757.6% | +131.7% | −99.1% | −100.0% | — | +634.2% | −99.8% | +100.0% | −50.0% | −50.0% |
| Margins | ||||||||||||
| EBITDA margin | <−999% | <−999% | <−999% | −334.1% | <−999% | — | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Operating margin | <−999% | <−999% | <−999% | −336.4% | <−999% | — | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | −341.7% | <−999% | — | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | −858.1% | −348.5% | <−999% | — | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Cash flow | ||||||||||||
| Cash from operations | −39 | −79 | −58 | −55 | −49 | −57 | −61 | −29 | −30 | −5 | −3 | −3 |
| Capital spending | 1 | 2 | 1 | 1 | 0 | 10 | 3 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −40 | −80 | −59 | −55 | −50 | −67 | −65 | −29 | −30 | −5 | −3 | −3 |
| Stock-based pay | 3 | 5 | 8 | 8 | 8 | 7 | 11 | 4 | 3 | 0 | 1 | 1 |
| Free cash flow after stock pay | −43 | −85 | −67 | −64 | −57 | −74 | −76 | −33 | −33 | −5 | −4 | −4 |
| Balance sheet | ||||||||||||
| Cash | 105 | 73 | 81 | 71 | 62 | 115 | 76 | 39 | 6 | 1 | 1 | 0 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 24 | 17 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −105 | −73 | −81 | −71 | −62 | −115 | −52 | −22 | −6 | −1 | −1 | −0 |
| Diluted shares | — | — | — | — | — | 1m | 1m | 1m | 2m | 2m | 2m | 2m |
| Returned to shareholders | ||||||||||||
| Buybacks | 0 | 1 | 0 | 0 | 2 | — | 0 | 0 | 0 | — | — | — |
| Total returned | 0 | 1 | 0 | 0 | 2 | — | 0 | 0 | 0 | — | — | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 0 | 4 | 2 | 0 | 0 | 3 | 0 | 0 |
| EBITDA | −1,150 | −756 | −1,092 | −1,039 | −1,187 | −900 | −1,004 | −943 |
| Operating income | −1,150 | −755 | −1,092 | −1,039 | −1,187 | −907 | −1,012 | −952 |
| Net income | −1,127 | −742 | −1,073 | −1,051 | −1,159 | −893 | −1,006 | −952 |
| Diluted EPS | −$0.70 | −$0.46 | −$0.67 | −$0.63 | −$0.55 | −$0.36 | −$0.59 | −$0.41 |
| Growth (year on year) | ||||||||
| Revenue | — | +300.0% | +100.0% | −100.0% | — | −25.0% | −100.0% | — |
| Net income | — | −103.3% | — | — | — | — | — | — |
| Margins | ||||||||
| EBITDA margin | — | <−999% | <−999% | — | — | <−999% | — | — |
| Operating margin | — | <−999% | <−999% | — | — | <−999% | — | — |
| Net margin | — | <−999% | <−999% | — | — | <−999% | — | — |
| Free-cash-flow margin | — | <−999% | — | — | — | <−999% | — | — |
| Cash flow | ||||||||
| Cash from operations | −781 | −592 | −772 | −701 | −844 | −552 | −1,031 | −300 |
| Capital spending | 0 | 0 | — | — | — | 1 | — | 0 |
| Free cash flow | −781 | −592 | — | — | — | −553 | — | −300 |
| Stock-based pay | 80 | 81 | 68 | 184 | 301 | 243 | 141 | 246 |
| Free cash flow after stock pay | −861 | −673 | — | — | — | −796 | — | −546 |
| Last 12 months unless stated | TCRT | CELZ | LYEL | AIM | IBIO | LSTA | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $3000 | $3000 | $27000 | $95000 | $100000 | $100000 | $55m |
| Revenue growth, last 12 months | −50.0% | −50.0% | −55.0% | −21.5% | −75.0% | −90.7% | 12.2% |
| Revenue growth, 3-year average | −89.9% | −65.6% | −91.8% | −17.3% | −62.4% | — | 13.1% |
| Revenue growth, latest quarter | −100.0% | −100.0% | −50.0% | 4.0% | −100.0% | −100.0% | 10.2% |
| Gross margin | — | 66.9% | — | −968.5% | 59.9% | 7.7% | 82.9% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −191.1% |
| Operating margin, 3-year average | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −365.3% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −172.8% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −168.8% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −168.1% |
| Free-cash-flow margin, 3-year average | <−999% | — | <−999% | <−999% | <−999% | <−999% | −313.4% |
| Stock pay / revenue | >999% | 0.0% | >999% | 0.0% | >999% | >999% | 20.7% |
| Change in share count | 37.3% | 61.6% | — | 49.8% | 13.9% | 5.1% | 8.3% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Blackrock, Inc. | $48,258 | 21K | 23.6% | 0.0% |
| Geode Capital Management, LLC | $43,753 | 19K | 21.4% | ▼ 14.2% |
| Vanguard Fiduciary Trust Co | $35,023 | 15K | 17.1% | 0.0% |
| Vanguard Capital Management LLC | $31,782 | 14K | 15.5% | 0.0% |
| Citadel Advisors LLC | $26,826 | 12K | 13.1% | ▲ 12.8% |
| Osaic Holdings, Inc. | $3,907 | 2K | 1.9% | ▼ 2.7% |
| Tower Research Capital LLC (TRC) | $3,663 | 2K | 1.8% | ▲ 2.4% |
| Arax Advisory Partners | $2,749 | 1K | 1.3% | New |
| UBS Group AG | $2,242 | 1K | 1.1% | ▼ 56.4% |
| Morgan Stanley | $1,889 | 1K | 0.9% | ▲ 28.0% |
| Vanguard Global Advisers, LLC | $1,132 | 1K | 0.6% | 0.0% |
| Royal Bank Of Canada | $1,000 | 0K | 0.5% | ▲ 102.7% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Alaunos Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around January 10, 2025 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
